Ch Biotech R And D Co Sustainability Profile
Ch Biotech R&D Co., a leading player in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia. Founded in 2002, the company has established itself as a pioneer in biopharmaceutical research and development, focusing on innovative solutions for healthcare challenges. Specialising in the development of biologics and biosimilars, Ch Biotech R&D Co. is recognised for its commitment to quality and scientific excellence. Their core products include advanced therapeutic proteins and monoclonal antibodies, which are distinguished by their efficacy and safety profiles. With a strong market position, Ch Biotech R&D Co. has achieved significant milestones, including successful collaborations with global pharmaceutical firms. Their dedication to research and development continues to drive advancements in the biotechnology industry, making them a trusted name in biopharmaceutical innovation.
DitchCarbon Score
How does Ch Biotech R And D Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ch Biotech R And D Co's score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ch Biotech R And D Co's reported carbon emissions
In 2022, CH Biotech R&D Co., based in Taiwan (TW), reported total carbon emissions of approximately 4,000,000 kg CO2e. This figure includes 437,910 kg CO2e from Scope 1 emissions, 3,260,880 kg CO2e from Scope 2 emissions, and 140,920 kg CO2e from Scope 3 emissions. The previous year, 2021, saw similar emissions with Scope 1 at 444,390 kg CO2e, Scope 2 at 3,458,040 kg CO2e, and Scope 3 at 92,920 kg CO2e. Despite these figures, CH Biotech R&D Co. has not set specific reduction targets or initiatives as part of their climate commitments. There are no reported climate pledges or SBTi (Science Based Targets initiative) targets, indicating a lack of formalised strategies for emissions reduction. The company’s emissions data is not cascaded from a parent organisation, reflecting its independent reporting status. Overall, while CH Biotech R&D Co. has disclosed its emissions across all relevant scopes, it currently lacks defined reduction initiatives or commitments to mitigate its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 444,390 | 000,000 |
| Scope 2 | 3,458,040 | 0,000,000 |
| Scope 3 | 92,920 | 000,000 |
How Carbon Intensive is Ch Biotech R And D Co's Industry?
How Carbon Intensive is Ch Biotech R And D Co's Location?
Ch Biotech R And D Co's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ch Biotech R And D Co has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
